p53 alterations in chemically induced hamster cheek-pouch lesions

Molecular Carcinogenesis

Volumn 16, Issue 4, 1996, Pages 197-202

  Gimenez Conti, Irma B ^a   LaBate, Michael ^a   Liu, Feng ^a   Osterndorff, Elizabeth ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

7,12 Dimethylbenz a anthracene; Hamster cheek pouch; Mutation; p53; Squamous cell carcinoma

Indexed keywords

DIMETHYLBENZ[A]ANTHRACENE; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CHEEK POUCH; CONTROLLED STUDY; GENE MUTATION; HAMSTER; MALE; MOUTH CANCER; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; BASE SEQUENCE; CARCINOGENS; CARCINOMA, SQUAMOUS CELL; CHEEK; CRICETINAE; DISEASE MODELS, ANIMAL; EXONS; GENES, P53; IMMUNOHISTOCHEMISTRY; MALE; MESOCRICETUS; MOLECULAR SEQUENCE DATA; MOUTH NEOPLASMS; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029782884     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199608)16:4<197::AID-MC3>3.0.CO;2-D     Document Type: Article

References (36)

1. Vogelstein B. A deadly inheritance. Nature 348:681-682, 1990.
2. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 253:49-53, 1991.
3. Levine AJ, Momand J, Finaly CA. The p53 tumor suppressor gene. Nature 351:453-456, 1991.
4. Vogelstein B, Kinzler KW. p53 function and disfunction. Cell 70:523-526, 1992.
5. Momand J, Zambetti GP, Olson DC, George DL, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53 mediated transactivation. Cell 69:1237-1245, 1992.
6. Donehower LA, Bradley A. The tumor suppressor p53. Biochim Biophys Acta 1155:181-205, 1993.
7. Coltrera MD, Zarbo RJ, Sakr WA, Gown AM. Markers for dysplasia of the upper aerodigestive tract. Am J Pathol 141:817-825, 1992.
8. Warnakulasuriya KAAS, Johnson NW. Expression of p53 mutant nuclear phosphoprotein in oral carcinoma and potentially malignant oral lesions. J Oral Pathol Med 21:404-408, 1992.
9. Wang L-D, Hong Y-Y, Qiu S-L, Gao H, Yang CS, Accumulation of p53 protein in human esophageal precancerous lesions: A possible early biomarker for carcinogenesis. Cancer Res 53:1783-1787, 1993.
10. Shin DM, Kim J, Ro JY, et al. Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 54:321-326, 1994.
11. Navone NM, Troncoso P, Pisters LL, et al. p53 accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85:1657-1669, 1993.
12. Ruggeri B, Caamano J, Goodrow T, et al. Alterations of the p53 tumor suppressor gene during mouse skin tumor progression. Cancer Res 51:6615-6621, 1991.
13. Gimenez-Conti IB, Shin DM, Bianchi AB, et al. Changes in keratin expression during 7,12-dimethylbenz[a]anthracene-induced hamster cheek pouch carcinogenesis Cancer Res 50:4441-4445, 1990.
14. Sklar G, Schwartz J, Trickier DP, Niukian K. Regression by vitamin E of experimental oral cancer. J Natl Cancer Inst 78:987-992, 1987.
15. Suda D, Schwartz J, Sklar G. Inhibition of experimental oral carcinogenesis by topical β-carotene. Carcinogenesis 7:711-715, 1986.
16. Gimenez-Conti IB, Slaga TJ. The hamster cheek pouch carcinogenesis model J Cell Biochem Supp 17B:83-90, 1993.
17. Chang K-W, Mangold KA, Hubchak S, Laconi S, Scarpelli DG. Genomic p53 mutation in a chemically induced hamster pancreatic ductal adenocarcinoma. Cancer Res 54:3878-3883, 1994.
18. Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T. Detection of polymorphism of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 86:2766-2770, 1989.
19. Legros Y, McIntyre P, Soussi T. The cDNA cloning and immunological characterization of hamster p53. Gene 112:247-250, 1992.
20. Goodrow TR, Storer RD, Leander KR, Prahalada SR, VanZweiten MJ, Bradley MO. Murine p53 intron sequences 5-8 and their use in polymerase chain reaction/direct sequence analysis of p53 mutation in CD-1 mouse liver and lung tumors. Mol Carcinog 5:9-15, 1992
21. Visakorpi T, Kallioniemi OP, Heikkinen A, Koivula T, Isola J. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 84:883-887, 1992.
22. Pignatelli M, Stamp GWH, Kafiri G, Lane D, Bodmer WF. Overexpression of p53 nuclear oncoprotein in colorectal adenomas. Int J Cancer 50:683-688, 1992.
23. Martin HM, Filipe MI, Morris RW. p53 expression and prognosis in gastric carcinoma. Int J Cancer 50:859-862, 1992.
24. Iggo R, Gatter K, Bartek J, Lane DP, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335:675-679, 1990.
25. Marks JR, Davidoff AM, Kens BJ. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 51:2979-2984, 1991.
26. Wang JL, Zhang ZJ, Hartman M, et al. Detection of Tp53 gene mutation in human meningionias: A study using immunohistochemistry, polymerase chain reaction/single strand conformation polymorphism and DNA sequencing techniques on paraffin-embedded samples. Int J Cancer 64:223-228, 1995.
27. Bjelogrlic NM, Makinen M, Stenback F, Vahakangas K. Benzo[a]pyrene-7,8-diol-9,10-epoxide-DNA adducts and increased p53 protein in mouse skin. Carcinogenesis 15:771-774, 1994.
28. Ruggeri B, DiRado M, Zhang SY, Bauer B, Goodrow T, Klein-Szanto AJP. Benzo[a]pyrene-induced murine skin tumors exhibit frequent and characteristic G to T mutation in the p53 gene. Proc Natl Acad Sci USA 90:1013-1017, 1993.
29. Kemp CJ, Donehower LA, Bradley A, Balmain A. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell 74:813-822, 1993.
30. Suzuki H, Takahashi T, Kuroishi T, et al. p53 mutations in non-small cell lung cancer in Japan: Association between mutations and smoking. Cancer Res 52:734-736, 1992
31. Shea CR, McNutt NS, Volkenandt M, Lugo J, Prioleau PG, Albino AP. Overexpression of p53 protein in basal cell carcinomas of human skin. Am J Pathol 1411:25-29, 1992.
32. Hollstein MC, Metcalf RA, Welsh JA, Montesano R, Harris CC. Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci USA 87:9958-9961, 1990.
33. Ahomadegbe JC, Barrois M, Fogel S, et al. High incidence of p53 alterations (mutation, deletion, Overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein Overexpression in normal epithelium and in early non-invasive lesions. Oncogene 10:1217-1227, 1995.
34. Sauter ER, Cleveland D, Track B, Ridge JA, Klein-Szanto AJP. p53 is overexpressed in fifty percent of pre-invasive lesions of head and neck epithelium. Carcinogenesis 15:2269-2274, 1994.
35. Caamano J, Zhang SY, Rosvold EA, Bauer B, Klein-Szanto AJP. p53 alterations in human squamous cell carcinomas and carcinoma cell lines. Am J Pathol 1424:1131-1139, 1993.
36. Peller S, Halery A, Slutzkis S, Kopilova Y, Rotter V. p53 mutations in matched primary and metastatic human tumors. Mol Carcinog 13:166-172, 1995.